Perspective Life (300642.SZ): 2023 equity distribution, 10 distributions of 1.5 yuan, share registration date May 22
On May 15, Ge Longhui | Vision Life (300642.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 1.500,000 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital excluding 162,180,091 shares after 1,946,150 shares have been repurchased. The share registration date for this equity distribution is May 22, 2024, and the ex-dividend date is May 23, 2024.
Insight Life (300642.SZ): Plans to increase capital in the holding subsidiary Maze Biotech
On May 14, Ge Longhui Life (300642.SZ) announced that due to biotechnology's business development needs, it plans to increase its registered capital from RMB 35 million to RMB 38.5 million. The total amount of capital increase is RMB 20 million. Shanghai Zhang Keling Yifan Venture Capital Center (limited partnership) and the company jointly pledged, and the rest of the shareholders relinquished their priority subscription rights. Among them: Zhang Ke Lingyi invested RMB 11 million to subscribe to Maxbiotech with an additional registered capital of RMB 1.925 million; the company invested RMB 9 million to subscribe to Maxim Biotech with an additional registered capital of 157
Perspective Life (300642.SZ): Repurchase completed, 1.19% of shares have been repurchased
Gelonghui, May 6, 丨 Vision Life (300642.SZ) announced that as of the announcement disclosure date, the company's share repurchase was completed. The actual repurchase period was from February 20, 2024 to April 29, 2024. During this period, the company carried out a total of 1,946,150 shares through a dedicated repurchase securities account, accounting for 1.19% of the company's current total share capital. The highest transaction price was 14.49 yuan/share. The minimum transaction price was 12.34 yuan/share, and the total amount paid was RMB 12.34 per share. RMB 25,979,178.00 (excluding delivery)
Perspective Life (300642) 2023 Report and 2024 Quarterly Report Review: Performance Under Pressure Due to Collection and Medical Compliance Actions
Matters: The company released financial reports. In '23, the company achieved revenue of 543 million yuan (-24.19%), net profit to mother of 89 million yuan (-28.34%), and deducted non-net profit of 64 million yuan (-37.11%)
Vision Life (300642.SZ): Net loss of 4.4879 million yuan in the first quarter
On April 22, GLONGHUI (300642.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 93.0721 million yuan, down 23.61% year on year; net profit attributable to shareholders of listed companies was 4.4879 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 5,617,500 yuan; basic earnings per share - 0.0277 yuan.
Insight Life (300642.SZ) Jiangxi subsidiary obtained 8 medical device registration certificates
Zhitong Finance App News, Taojing Life (300642.SZ) announced that Jiangxi Tuojing Life Technology Co., Ltd. (hereinafter referred to as the “subsidiary” or “Jiangxi Toujing”), a wholly-owned subsidiary of the company, recently obtained 8 medical device registration certificates issued by the Jiangxi Drug Administration.
Express News | Insight Life: Shareholder Rongzhen Investment plans to reduce holdings by no more than 1%
A subsidiary of Toujing Life (300642.SZ) obtained a medical device registration certificate
Toujing Life (300642.SZ) announced that Jiangxi Tuojing Life Technology Co., Ltd., a wholly-owned subsidiary of the company, recently...
Vision Life (300642.SZ): Accumulated investment of 4,555 million yuan to buy back 0.21% of shares
Gelonghui, March 4, 丨 Vision Life (300642.SZ) announced that as of February 29, 2024, the company had repurchased 352,850 shares through a special stock repurchase account, accounting for 0.21% of the company's current total share capital. The highest price for this repurchase of shares was 13.25 yuan/share, the lowest transaction price was 12.36 yuan/share, and the total amount paid was RMB 4,555,125.00.
Insight Life (300642.SZ): Initial repurchase of 135,000 shares involving 1.7078 million yuan
Gelonghui, Feb. 20, 丨 Vision Life (300642.SZ) announced that on February 20, 2024, for the first time, the company repurchased 135,000 shares through a special stock repurchase account, accounting for 0.08% of the company's current total share capital. The highest price for this repurchase of shares was 12.72 yuan/share, the lowest transaction price was 12.36 yuan/share, and the total amount paid was RMB 1.7078 million (not including transaction fees).
The actual controller of Seojing Life (300642.SZ) proposed that the company spend 25 million yuan to 50 million yuan to buy back shares
Insight Life (300642.SZ) issued an announcement. The company recently received the company's actual controller, controlling shareholders, directors...
Vision Life (300642.SZ): Plans to establish a wholly-owned subsidiary in Singapore for 2 million US dollars
On January 4, Greenview Life (300642.SZ) announced that the company plans to establish a wholly-owned subsidiary TELLGEN SINGAPORE PTE in Singapore through foreign direct investment. LTD. (Chinese name: Toujing Life Technology (Singapore) Co., Ltd.) (Tentative name, specific name is based on the final approved name, hereinafter referred to as “Singapore subsidiary”), mainly engaged in R&D, production, sales and technical services of in vitro diagnostic reagents and instruments. The investment amount is 2 million US dollars, and the funding source is its own capital.
Perspective Life (300642.SZ): Currently, the company headquarters and industrialization base are in the construction stage, and the estimated completion time of infrastructure is before June 2025
On December 26, Gelonghui, on the investor interactive platform, some investors asked Perspective Life (300642.SZ), “When is the planned completion time for the new plant? When do you think you'll move in?” The company replied that the company headquarters and industrialization base are currently in the construction stage. The estimated time for completion of the infrastructure is before June 2025, and the later stages will still need to go through hardcover before it can be relocated. The company will pay close attention to the progress of the project and actively promote the construction and implementation of the project.
Tojing Life (300642.SZ): The main end customers are hospitals at all levels in China, medical examination centers, independent laboratories, etc., of which tertiary hospitals account for about 70% of hospital customers
On December 26, Glonghui, on the investor interactive platform, some investors asked Toujing Life (300642.SZ), “How many customers have there been in Toujing Life's top three hospitals and medical institutions so far? What are the main products offered?” The company replied that the company's main end customers are hospitals, medical examination centers, independent laboratories, etc. at all levels in China. Among them, tertiary hospitals account for about 70% of hospital customers, and mainly provide tumor marker test kits, autoimmune test kits, HPV nucleic acid testing products, etc.
Toujing Life (300642.SZ), a specific shareholder of Rongzhen Investment, reduced its holdings by a cumulative total of 2.03% at the end of the reduction period
Toujing Life (300642.SZ) announced that the company's specific shareholder Rongzhen Investment's holdings reduction period has expired, and its cumulative holdings have been reduced...
Perspective Life (300642) Review of the 2023 Third Quarter Report: Q3 revenue growth was pressured, and gross margin recovered relatively well
Matters: The company released its three-quarter report for 2023. Revenue for the first three quarters was 401 million yuan (-22.62%), net profit was 43 million yuan (-51.24%), and net profit after deducting non-net profit was 28 million yuan (-6)
[Instant Analysis of BT Financial Report] Perspective Life 2023 Third Quarter Report: Balance Ratio Decreased, Operating Income Decreased, Net Cash Flow Decreased
Announcement time of this financial report: 2023-10-24 18:34:36 Perspective Life Company (stock code: 300642) is a company focusing on R&D, production and sales of its own brand of in vitro diagnostic products. The company's main business includes products in various fields such as full cancer testing, autoimmunity, cardiovascular disease, pathogen infections, and reproductive health. The company's products have covered more than 2,100 end users in 31 provinces and cities across the country, and are widely used in hospitals, medical examination centers and independent laboratories at all levels. The company adheres to the concept of “connecting with global technical resources and building on local innovation and creation” and continues
Changes in A-shares | Perspective Life fell more than 7%, close to low listing prices, Q3 net profit fell 82% year-on-year
Glonghui, October 25 | Perspective Life (300642.SZ) continues to decline. Currently, it has dropped by more than 7%. At 1,675 yuan, it is close to the low listing price, with a total market value of less than 3 billion yuan. The company announced last night that its main revenue for the third quarter was 125 million yuan, down 36.73% year on year; net profit for Gimu was 8.053 million yuan, down 82.06% year on year.
Perspective Life (300642.SZ) plans to transfer 3.46% of the shares of the holding subsidiary Pulse Biotech to promote the sustainable and stable development of Pulse Biotech
Teloscopic Life (300642.SZ) announced that the company and its wholly-owned subsidiary Shanghai Teloscopic Diagnostic Technology Co., Ltd. (“Transparent...
Perspective Life (300642): Reagent revenue grew rapidly in the second quarter, and gross margin clearly rebounded
Matters: The company released its semi-annual report for 23 years. The company achieved revenue of 276 million yuan (-13.92%), net profit of 35 million yuan (-19.14%), minus non-net profit of 26 million yuan (-9.86%).
No Data